Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements.

about

Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements.

Item

http://www.wikidata.org/entity/Q55018427

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Decitabine demonstrates antile ...... kemia with MLL rearrangements.

@en

Decitabine demonstrates antile ...... kemia with MLL rearrangements.

@nl

type

Item

label

Decitabine demonstrates antile ...... kemia with MLL rearrangements.

@en

Decitabine demonstrates antile ...... kemia with MLL rearrangements.

@nl

prefLabel

Decitabine demonstrates antile ...... kemia with MLL rearrangements.

@en

Decitabine demonstrates antile ...... kemia with MLL rearrangements.

@nl

P1476

Decitabine demonstrates antile ...... kemia with MLL rearrangements.

@en

P2093

A Richter

http://www.w3.org/2001/XMLSchema#string

A Sekora

http://www.w3.org/2001/XMLSchema#string

B J Krause

http://www.w3.org/2001/XMLSchema#string

B Vollmar

http://www.w3.org/2001/XMLSchema#string

C Junghanss

http://www.w3.org/2001/XMLSchema#string

C Konkolefski

http://www.w3.org/2001/XMLSchema#string

C Roolf

http://www.w3.org/2001/XMLSchema#string

G Knuebel

http://www.w3.org/2001/XMLSchema#string

H Murua Escobar

http://www.w3.org/2001/XMLSchema#string

J Stenzel

http://www.w3.org/2001/XMLSchema#string

P2860

Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.

Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.

A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.

Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.

Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.

In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice.

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

P2888

s13045-018-0607-3

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13045-018-0607-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1103815334

http://www.w3.org/2001/XMLSchema#string

P698

29728108

http://www.w3.org/2001/XMLSchema#string

P932

5936021

http://www.w3.org/2001/XMLSchema#string